Macular ischemia associated with imatinib mesylate therapy for chronic myeloid leukemia.
Imatinib mesylate (Gleevec, East Hanover, NJ) is a drug approved for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or Kit-positive gastrointestinal stromal tumors. A case of ischemic maculopathy associated with imatinib mesylate therapy is reported. A 62-year-old woman with a 16-year history of CML was treated with imatinib mesylate, initially at a daily dose of 400 mg that was decreased to 300 mg due to systemic side effects. Several weeks after beginning imatinib mesylate therapy, she developed blurred vision (greater in the left eye than in the right eye). Fundus examination of both eyes revealed retinal telangiectasia with intraretinal hemorrhages and perifoveal retinal telangiectasia. Fluorescein angiography showed macular ischemia (greater in the left eye than in the right eye). Late perifoveal leakage was present surrounding the macular ischemic zone. Visual acuity was reduced to 20/30 in the right eye and 20/100 in the left eye, which did not improve over 10 months of follow-up. Imatinib mesylate may be associated with ischemic maculopathy that can severely compromise vision. It may be necessary for patients receiving this therapy to be monitored for associated visual symptoms and funduscopic abnormalities.